Notes
JBH-492 (Novartis) = first-in-class anti-CCR7 ADC: humanized Fc-silenced IgG1 conjugated site-specifically to maytansinoid DM4 via a cleavable linker, DAR 3.8. Trial NCT04240704 (Phase 1/Ib, r/r CLL + NHL) is terminated/discontinued; no formal RP2D/MTD declared.
DENOMINATOR CAVEAT (important): two analysis populations appear across sources and are tagged per-row. (1) N=16 treated/evaluable -> AACR 2024 CT174 TRAE table: eye toxicity any-grade 56.3%, blurred vision 44%, AST increased 50%, fatigue 44%, diarrhoea 43%, overall any-Grade-3 TRAE 12.5% (2/16), 1 DLT = G3 thrombocytopenia lasting 13 d. (2) N=25 enrolled -> PatSnap/Synapse aggregated profile: anaemia 32%, thrombocytopenia 28%, neutropenia 20%, dry eye 20%, SAE 24%, any-AE 92%. The 56.3%/44% ocular figures (the reason this ADC qualifies) are from the N=16 set; dry eye 20% and the haematology %s are from the N=25 aggregate.
Cohort: 25 enrolled = 24 NHL (ATLL 3, CTCL 4, DLBCL 7, FL 1, MCL 1, MZL 2, PTCL 3, others 3) + 1 CLL; median age 69; mean exposure 13.5 wks. Efficacy: ORR 6/16 (37.5%; 1 CR, 5 PR); responses at 2.4-3.6 mg/kg.
ADCdb cross-ref IDs: ADC DRG0WXNKG; Antibody ANI0PZSCN; Antigen TAR0ZYPEF; Payload PAY0GTSVM; Target PATR0CXRBX. ADCdb has NO linker entry (conjugate type/linker class/cleavage/attachment all listed undisclosed), so the adcdb{} linker physchem fields are correctly blank. Note slight tension: ADCdb lists conjugation as undisclosed, but the AACR CT174 and ASH 2022 abstracts both state 'site-specific' conjugation and a 'cleavable' linker (specific chemistry not disclosed; DM4 cleavable linkers are typically reducible disulfides such as SPDB/sulfo-SPDB, but this is NOT stated for JBH-492 so left unasserted).
Payload DM4 physchem from PubChem CID 11686439 per DB convention: MW 780.4, XLogP3 3.2, TPSA 157, formal charge 0 (maytansinoids neutral at pH 7.4, no ionizable basic centre). ADCdb computes a different XLogP (5.0) by a different algorithm; PubChem value retained per convention. logD7.4 and pKa not available in PubChem/literature -> blank. DM4 is bystander-active (lipophilic S-methyl-DM4 metabolite), same payload class as mirvetuximab soravtansine.
Ocular interpretation: dominant ocular PTs are blurred vision (visual) + dry eye (ocular surface); no conjunctivitis or explicit keratopathy/keratitis % reported -> ocular_surface_subtype = Mixed (DM4 off-target corneal mechanism likely). Ocular-specific Grade 3+ NOT separately reported -> oae_g3plus_pct left blank (not zero). Reversibility not explicitly stated for JBH-492, though ocular AEs were managed by dose reduction (DM4-class ocular toxicity is typically reversible). CTCAE version not stated (trial 2020-2024, likely v5.0) -> ctcae_version left blank.
Not represented in toxicity_rows because no matching organ_system enum: fatigue 44% (N=16). Pulmonary, Neurologic-PN (peripheral neuropathy) and Infusion-reaction AEs were NOT reported in accessible sources -> intentionally omitted (blank = not in literature, not zero). Primary clinical/ocular evidence is conference-abstract grade (Tier D); composition/payload facts Tier C. AACR CT174, ASH 2022 (Blood) and the ADC Review/aacrjournals pages returned HTTP 403; clinical figures were obtained via WebSearch snippets of those abstracts plus the PatSnap/Synapse and ADC Review drug profiles.